Trauma Triage and Trauma System Performance

Por Johnson, Gary
Publicado no West J Emerg Med (2016)

Management of Sickle Cell Disease Super Utilizers

Por Johnson, Gary A.
Publicado no West J Emerg Med (2017)

Noncanonical Function of MEKK2 and MEK5 PB1 Domains for Coordinated Extracellular Signal-Regulated Kinase 5 and c-Jun N-Terminal Kinase Signaling

Por Nakamura, Kazuhiro, Johnson, Gary L.
Publicado em 2007

The c-Jun Kinase/Stress-activated Pathway: Regulation, Function and Role in Human Disease

Por Johnson, Gary L., Nakamura, Kazuhiro
Publicado em 2007

Sequence patches on MAPK surfaces define protein-protein interactions

Por Johnson, Gary L, Gomez, Shawn M
Publicado em 2009

Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT

Por Abell, Amy N., Johnson, Gary L.
Publicado no Curr Pathobiol Rep (2014)

MEK Inhibition in Non-Small Cell Lung Cancer

Por Stinchcombe, Thomas E., Johnson, Gary L.
Publicado no Lung Cancer (2014)

Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-a...

Por Knall, Cindy, Worthen, G. Scott, Johnson, Gary L.
Publicado em 1997

Data-driven modeling of cellular stimulation, signaling and output response in RAW 264.7 cells

Por Wu, Yang, Johnson, Gary L, Gomez, Shawn M
Publicado em 2008

MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis

Por Pham, Trang T., Angus, Steven P., Johnson, Gary L.
Publicado em 2013

Assessing adaptation of the cancer kinome in response to targeted therapies

Por Zawistowski, Jon S., Graves, Lee M., Johnson, Gary L.
Publicado no Biochem Soc Trans (2014)

Identification of Ponatinib and Other Known Kinase Inhibitors with Potent MEKK2 Inhibitory Activity

Por Ahmad, Syed, Johnson, Gary L., Scott, John E.
Publicado no Biochem Biophys Res Commun (2015)

Landscaping a chromatin response to MEK inhibition

Por Zawistowski, Jon S., Goulet, Daniel R., Johnson, Gary L.
Publicado no Cell Cycle (2017)

Pharmacologic targeting of drug-induced enhancers

Por Zawistowski, Jon S., Bevill, Samantha M., Johnson, Gary L.
Publicado no Oncoscience (2017)

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer

Por Bevill, Samantha M., Zawistowski, Jon S., Johnson, Gary L.
Publicado no Mol Cell Oncol (2017)

Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer

Por Jordan, Nicole Vincent, Johnson, Gary L, Abell, Amy N
Publicado em 2011

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains

Por Stuhlmiller, Timothy J., Miller, Samantha M., Johnson, Gary L.
Publicado no Mol Cell Oncol (2015)

Identification of the glucagon receptor in rat liver membranes by photoaffinity crosslinking

Por Johnson, Gary L., MacAndrew, Vincent I., Pilch, Paul F.
Publicado em 1981

Phenotypic Characterization of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis

Por Katz, Martin L., Johnson, Gary S., Tullis, Gregory E., Lei, Bo
Publicado em 2007

Fluorochrome-Labeled Inhibitors of Caspases: Convenient In Vitro and In Vivo Markers of Apoptotic Cells for Cytometric Analysis

Por Darzynkiewicz, Zbigniew, Pozarowski, Piotr, Lee, Brian W., Johnson, Gary L.
Publicado em 2011